Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and l-DOPA-Induced Dyskinesia

被引：36

作者：

Ferreira Junior, Nilson Carlos ^{[1
,2
]}

dos-Santos-Pereira, Mauricio ^{[2
,3
]}

Guimaraes, Francisco Silveira ^{[1
,2
]}

Del Bel, Elaine ^{[1
,2
,3
]}

机构：

[1] Univ Sao Paulo, FMRP, Dept Pharmacol, Campus USP,Av Bandeirantes 13400, BR-14049900 Ribeirao Preto, SP, Brazil

[2] Univ Sao Paulo, Ctr Interdisciplinary Res Appl Neurosci NAPNA, Sao Paulo, Brazil

[3] Univ Sao Paulo, FORP, Dept Basic & Oral Biol, Campus USP,Av Cafe S-N, BR-14040904 Ribeirao Preto, SP, Brazil

来源：

NEUROTOXICITY RESEARCH | 2020年 / 37卷 / 01期

基金：

巴西圣保罗研究基金会;

关键词：

Cannabinoid system; Endocannabinoids; Cannabinoid receptor (CB); Transient receptor potential vanilloid receptor (TRPV); Peroxisome proliferator-activated receptor (PPAR); Neuroinflammation; NF-KAPPA-B; LEVODOPA-INDUCED DYSKINESIA; ACTIVATED-RECEPTOR-GAMMA; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MOUSE MODEL; DISTINCT NEURONAL SUBPOPULATIONS; RECREATIONAL PHYSICAL-ACTIVITY; NONHUMAN PRIMATE MODEL; RAT MODEL; BASAL GANGLIA; IN-VITRO;

D O I：

10.1007/s12640-019-00109-8

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Parkinson's disease (PD) and l-DOPA-induced dyskinesia (LID) are motor disorders with significant impact on the patient's quality of life. Unfortunately, pharmacological treatments that improve these disorders without causing severe side effects are not yet available. Delay in initiating l-DOPA is no longer recommended as LID development is a function of disease duration rather than cumulative l-DOPA exposure. Manipulation of the endocannabinoid system could be a promising therapy to control PD and LID symptoms. In this way, phytocannabinoids and synthetic cannabinoids, such as cannabidiol (CBD), the principal non-psychotomimetic constituent of the Cannabis sativa plant, have received considerable attention in the last decade. In this review, we present clinical and preclinical evidence suggesting CBD and other cannabinoids have therapeutic effects in PD and LID. Here, we discuss CBD pharmacology, as well as its neuroprotective effects and those of other cannabinoids. Finally, we discuss the modulation of several pro- or anti-inflammatory factors as possible mechanisms responsible for the therapeutic/neuroprotective potential of Cannabis-derived/cannabinoid synthetic compounds in motor disorders.

引用

页码：12 / 29

页数：18

共 259 条

[1] Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp I [J].